Tag: Amifampridine

According to the Myasthenia Gravis Foundation of America, treatments for myasthenic disorders have advanced significantly, offering effective options to manage symptoms and improve quality of life. This article provides a comprehensive overview of the medications used for myasthenic syndrome, focusing on the two most common types: Myasthenia Gravis (MG) and Lambert-Eaton Myasthenic Syndrome (LEMS).

Approximately 60% of cases of Lambert-Eaton Myasthenic Syndrome (LEMS) are associated with an underlying malignancy, most commonly small-cell lung cancer. The first line treatment for Lambert Eaton syndrome aims to enhance neuromuscular transmission and, in paraneoplastic cases, treat the underlying cancer.

In 2018, the U.S. Food and Drug Administration (FDA) approved the first and only evidence-based medication specifically for adults with Lambert-Eaton Myasthenic Syndrome (LEMS). For patients wondering what is the new treatment for LEMS, the primary focus has been on this prescription drug, amifampridine (Firdapse), along with established immunomodulatory strategies and treatment for any associated cancers.